IRCT20200105046010N79招募中Unknown
Bioequivalence study of Tofacitinib 10 mg tablet manufactured by Cobel daru versus originator brand in healthy volunteers in the fasted condition
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •alcohol and drug addiction
- •history of allergy to Tofacitinib
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence study of Rhofinib tablet with brand drugs (XELJANZ® 10 mg, Pfizer, Ireland)IRCT20200105046010N38anoalvand Pharmaceutical Co24
已完成
1 期
Tofacitinib Bioequivalence Study Comparing Tablets And CapsulesHealthyNCT01599377Pfizer50
尚未招募
4 期
sefulness of tofacitinib in atopic dermatitisCTRI/2024/08/072026AIIMS Bhubaneswar
尚未招募
Unknown
A comparison of efficacy and safety of oral tofacitinib vs methotrexate in management of moderate to severe chronic plaque psoriasisCTRI/2023/06/053443one
招募中
1 期
Effects of Tofacitinib on Ulcerative Colitis patientslcerative Colitis.Ulcerative colitisIRCT20181217042020N2Digestive Disease Research Institute of Tehran University of Medical Sciences40